# Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

> **NCT02166346** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 24 (actual)

## Conditions studied

- Transverse Myelitis
- Neuromyelitis Optica
- Idiopathic Transverse Myelitis
- Myelitis NOS

## Interventions

- **DRUG:** Dalfampridine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02166346
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-01-08
- **Final completion:** 2017-01-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166346, "Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02166346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*